Belimumab
Treatment for Lupus
Typical Dosage: 10 mg/kg IV every 4 weeks or 200 mg SC weekly
Effectiveness
75%
Safety Score
55%
Clinical Trials
63
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
10 mg/kg IV every 4 weeks or 200 mg SC weekly
Time to Effect
3-6 months
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$35,000
Monitoring:$700
Side Effect Mgmt:$400
Total Annual:$36,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$130,000/QALY
QALYs Gained
0.25
Outcome-Based Costs
Cost per Responder
$80,222
Cost per Remission
$144,400
Belimumab Outcomes
for Lupus
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+45%
Remission Rate
+25%
Common Side Effects
Nausea, diarrhea
+12%
Infusion reactions
+12%
Infections (URI, UTI)
+18%
Depression, insomnia
+7%
Sources:
Active Clinical Trials
6 active trials recruiting for Belimumab in Lupus
Trial of Belimumab in Early Lupus
NCT03543839RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Manhasset, United States
Started: Sep 15, 2020
BENLYSTA® Special Drug Use Investigation
NCT03370263RECRUITING
600 participants
OBSERVATIONAL
Hiroshima, Japan
Started: Jan 15, 2018
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
NCT04179032ACTIVE NOT RECRUITINGPHASE2
25 participants
INTERVENTIONAL
Cincinnati, United States +10 more
Started: Nov 28, 2019
A Model About the Response of Belimumab in SLE
NCT04893161NOT YET RECRUITINGPHASE4
72 participants
INTERVENTIONAL
Started: Jun 1, 2024
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249RECRUITINGPHASE4
350 participants
INTERVENTIONAL
Anniston, United States +112 more
Started: Jun 6, 2024
Belimumab in SLE Synovial Inflammation and Lymph Nodes
NCT06327724RECRUITING
15 participants
OBSERVATIONAL
Amsterdam, Netherlands
Started: Sep 1, 2023
Completed Clinical Trials
12 completed trials for Belimumab in Lupus
Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
NCT00657007COMPLETEDPHASE1
70 participants
INTERVENTIONAL
Birmingham, United States +17 more
Started: Feb 1, 2002
Belimumab (BENLYSTA®) Pregnancy Registry
NCT01532310COMPLETED
77 participants
OBSERVATIONAL
Wilmington, United States +14 more
Started: Jul 16, 2012
Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry
NCT01729455COMPLETED
3.14K participants
OBSERVATIONAL
Birmingham, United States +178 more
Started: Feb 21, 2013
A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02
NCT00583362COMPLETEDPHASE2
298 participants
INTERVENTIONAL
Birmingham, United States +56 more
Started: May 4, 2005
Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus
NCT02880852COMPLETEDPHASE1
20 participants
INTERVENTIONAL
Shanghai, China +1 more
Started: Jan 23, 2017
A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
NCT00712933COMPLETEDPHASE3
738 participants
INTERVENTIONAL
Ciudad Autonoma de Buenos Aires, Argentina +109 more
Started: May 30, 2008
Transcriptional and Immune Parameters of Response to Belimumab
NCT04570306COMPLETED
85 participants
OBSERVATIONAL
Athens, Greece
Started: Dec 16, 2020
Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients
NCT02119156COMPLETEDPHASE3
80 participants
INTERVENTIONAL
Los Angeles, United States +19 more
Started: May 13, 2014
Efficacy and Safety of Belimumab in SLE Patients
NCT04515719COMPLETEDPHASE4
231 participants
INTERVENTIONAL
Shanghai, China
Started: Mar 10, 2021
BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115
NCT01597622COMPLETEDPHASE3
142 participants
INTERVENTIONAL
Chiba, Japan +26 more
Started: Jun 11, 2012
Synergetic B-cell Immodulation in SLE
NCT02284984COMPLETEDPHASE2
16 participants
INTERVENTIONAL
Leiden, Netherlands
Started: Mar 1, 2014
Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects
NCT04136145COMPLETEDPHASE1
36 participants
INTERVENTIONAL
Shanghai, China
Started: Oct 28, 2019
Showing 20 of 64 total trials